TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectivelyAn inhibitor of PI3-kinase 查看阿拉丁官网此产品相关对应页面:https://www.aladdin-e.com/zh_cn/T129620.html ...
Here, we describe the characterization of KTC1101, a novel pan-PI3K inhibitor that simultaneously targets tumor cell proliferation and the tumor microenvironment. Our studies demonstrate that KTC1101 significantly increases the anti-PD-1 efficacy in multiple pre-clinical mouse models. Methods: KTC1101 ...
Buparlisib is a novel pan-PI3K inhibitor that is currently in clinical development for various cancers, including primary and secondary brain tumours. Importantly however, earlier studies have revealed that sufficient brain penetration is a ...
Based on this knowledge, through a meta-analysis on the pre-existing preclinical data, we investigate the therapeutic effects of both PI3K pan-inhibitor and PI3K-δ selective inhibitor on features of allergic lung inflammation including inflammatory cell infiltrations into lungs and levels of various ...
Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: shedding new light on NVP-BKM120 mechanism of action. Int. J. Biochem. Cell Biol. 79, 308-317.Bashash D, Safaroghli-Azar A, Delshad M, Bayati S, Nooshinfar E, Ghaffari SH. Inhibitor of pan...
参考文献:Roper J, Richardson MP, Wang WV, et al. The dual PI3K/mTOR inhibitorNVP-BEZ235 induces tumor regression in a genetically engineered mouse model ofPIK3CA wild-type colorectal cancer. PLoS One. 2011;6(9):e25132. 文献摘要:使用NVP-BEZ235体外处理CRC细胞系会导致短暂的PI3K阻滞,mTORC1 /...
Given the observation that the majority of triple-negative breast tumors demonstrate activation of the PI3K pathway, we tested the pan-class I PI3K inhibitor buparlisib in this phase 2 trial. In a small subset of patients in whom paired baseline and on-treatment tumor biopsies were available, ...
First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors First- in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor...
The aim of the study was to assess in ovarian cancer preclinical models, the efficacy and tolerability of a dual PI3K mTOR inhibitor (PF-05212384 or gedatolisib) and a c-Met inhibitor (crizotinib) either as single agents or in combination. In vitro, both PF-05212384 and crizotinib showed...
Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer. Methods This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer. Patients ...